Thunder Biotech

Thunder Biotech is a biotechnology and pharmaceutical company based in the United States, founded in 2016. The company's flagship product, MOTO-CAR®, is an innovative macrophage technology designed to provide effective treatment for patients with solid tumors. Thunder Biotech is focused on developing patented MOTO-CAR™ technology, which involves genetically engineered CAR macrophages that re-educate Tumor Associated Macrophages to recognize and eliminate tumor cells. These engineered macrophages are armed with tumor-specific receptors that allow them to initiate tumor cell destruction, recruit natural T cell response, and provide a memory response to prevent tumor recurrence.

Traditional cancer treatments such as surgery, radiation, and chemotherapy often have limited efficacy and can be invasive and difficult to tolerate. Thunder Biotech aims to offer a more effective and humane therapy through its MOTO-CAR™ technology, addressing the limitations of current treatment methods.

The latest investment in Thunder Biotech is a $100.00K debt financing investment received on 09 February 2024. While the details of the investors involved in this financing round are not specified, the investment signifies continued interest and support for the company's innovative approach to immune-oncology and cancer treatment.